Liquid biopsy offers a quick and easy way to asses the tumor samples. It is a simple and non-invasive alternative to surgical biopsies which enables doctors to unfold information about a tumor through a blood sample. It detects epidermal growth factor receptor (EGFR ) gene mutations which help doctors to choose the right treatment for the right patient at the right time.
The liquidBiopsy is a non-invasive technology which makes expanding oncology research feasible and able to include cohorts that are unable to undergo a standard biopsy procedure. With a liquid biopsy, researchers can analyze biomarkers circulating in the bloodstream obtained through a conventional blood draw.
One of the worst parts about surgical biopsy is its inconvenience and pain. This problem has been tackled by liquid biopsy but the biggest benefit of liquid biopsy is being able to detect disease progression which is not usually seen from a tissue sample. In the longer run, liquid biopsies may be used to catch signs of cancer before symptoms arise.
Liquid Biopsy Companies
Below listed are a few thriving liquid biopsy companies to watch in 2019
Headquarter: Basel, Switzerland
Roche, the world’s largest biotech company, is a global pioneer in pharmaceuticals and diagnostics. It has branches fro medicines in oncology, infections, ophthalmology, etc. It has twenty-nine medicines included in the WHO model list of essential medicines. In addition to this, it is the first company to start a liquid biopsy.
Roche’s liquid biopsy can identify 70 of the most commonly mutated genes in tumors, including microsatellite instability (genomic signature), which will help to determine the type of immunotherapy-based treatment needed from a single blood sample. This company meets the need for comprehensive genomic profiling for people who have insufficient or inadequate tissue, including those with advanced non-small cell lung cancer.
Headquarter: Hilden, Germany
QIAGEN is an organization that leads the world in DNA, RNA and protein extraction, purification and stabilization for testing. It was started in the mid-1980s to provide a safer and easier way to handle the painstaking tasks in the laboratories. This company now has one of the best testing technologies in the world; a combination of hundreds of QIAGEN software that interpret the vast amount of information.
QIAGEN offers a complete and efficient workflow to facilitate liquid biopsy research. A complete package of collection and analysis is offered here. The collected sample is stabilized in tubes and a unique non-crosslinking material designed for sensitive cfDNA. The technologies here help a deep insight into the cfDNA, CTCs, and exosomes which are important for diagnosis and decision making.
Headquarter: California, United States
Biocept is an organization completely dedicated to improving the lives of cancer patients. They focus on developing innovative diagnostic solutions that give patients and doctors the information they need. It is a fully approved company by the states of California, Florida, Maryland, Pennsylvania, and Rhode Island which focuses on providing high-level, personalized service to our clients, addressing critical questions of interest.
Biocept is a trusted place by medical and surgical oncologists, pathologists, hospitals, cancer centers, universities, and pharmaceutical and clinical researchers. The results of Biocept have been widely used by doctors in thousands of patient cases. Biocept’s test menu focuses on cancer biomarkers that are based on guidelines listed by the National Comprehensive Cancer Network (NCCN). The obtained results have molecularly characterized tumor cells with evaluated changes in protein expression which is important for prognostic and therapeutic applications.
Headquarter: Utah, United States
Myriad Genetics has been leading molecular diagnostics for over 25 years. Founded in 1991, it is one of the first genomics companies in history. Today, Myriad is the pioneer and leader in, offering innovative products like diagnostic tests for hereditary cancer, urological cancer, autoimmune disorders, depression and other diseases that transform patients’ lives. The diagnostics tests here are designed to asses individual risks as well as its severity.
Its initial product was a 25 gene test which identified elevated risks for 8 different types of cancer using a blood sample. Myriad has now developed a suite of liquid biopsy tests. This company has now successfully completed more than 2 million accurate liquid biopsy tests so far.
Headquarter: Boston, United States
Thrive is an organization aiming to commercialize CancerSEEK, a DNA – and protein-based liquid biopsy. Thrive came out of the research of Bert Vogelstein, Keneth, and Nickolas Papadopoulos at John Hopkins University and intends to draw upon demographic and phenotypic information, behavioral data and information from retrospective clinical studies.
The test is designed to detect cancer by analyzing eight tumor-specific genomic mutations and associated protein biomarkers in plasmas to identify abnormalities that are common across multiple cancers. This organization also raised $110 million in series A funding.